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European consensus on grading bone marrow fibrosis
and assessment of cellularity
Regarding assessment of bone mar-row biopsy specimens, interest hasbeen recently reawakened in the
standardization of key histological param-
eters such as cellularity and fiber content.
It is noteworthy that age-related quantita-
tive changes in hematopoiesis must
always be kept in mind because these
have turned out to be predictive of ade-
quate cell yield for transplantation.1
Myelofibrosis is a concomitant cytokine-
mediated process of the bone marrow
stroma.2 It has been associated with many
different types of reactive conditions
including, among others, autoimmune and
granulomatous diseases3,4 and a variety of
neoplastic disorders.5,6 The latter include
myelodysplastic syndromes,7,8 acute
leukemic conditions9,10 and chronic myelo-
proliferative diseases (CMPD).11-15 In
chronic myelogenous leukemia (CML)
myelofibrosis was shown to be a signifi-
cant predictor of therapeutic efficacy and
outcome16-20 including engraftment after
transplantation.21,22 In this context, therapy-
related effects on the stabilization or regres-
sion of fibrosis in chronic idiopathic myelo-
fibrosis (CIMF) or myelofibrosis with
myeloid metaplasia have gained  increasing
attention,14,15 particularly when considering
novel therapeutic strategies.23-26
Scoring systems for normal values of
bone marrow cellularity27-31 and grading of
myelofibrosis32-35,31,36-40 are mainly based on
subjective evaluations by individual
pathologists using different grading sys-
tems (Table 1) and methods of processing
the trephine biopsies, i.e. plastic3,31,11-14 ver-
sus paraffin32,33,16,17,35,37,15,40 embedding. The
most frequently used grading systems
applied to assess myelofibrosis are essen-
tially based on the Baumeister scale32,35
which was modified by Manoharan.33 More
recent scoring systems are focused on
CMPD, and differentiate between reticulin
and collagen, on the basis of which grading
of myelofibrosis is assessed11,12,36,13-15,40 (Table
1). The grading of myelofibrosis into four
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Quantification of characteristic bone marrow biopsy features includes basic parame-
ters such as cellularity and fiber content. These are important to assess the dynam-
ics of disease processes with a significant impact on risk stratification, survival pat-
terns and, especially, therapy-related changes. A panel of experienced European
pathologists and a foreign expert  evaluated, at a multi-headed microscope, a large
number of representative slides of trephine biopsies from patients with myelofibrosis
in an attempt to reach a consensus on how to grade cellularity and fibrosis. This includ-
ed a critical evaluation of previously described scoring systems. During the microscop-
ic analysis and subsequent discussion and voting, the importance of age-dependent
decrease in cellularity was recognized. Grading of myelofibrosis was simplified by using
four easily reproducible categories including differentiation between reticulin and colla-
gen. A consensus was reached that the density of fibers must be assessed in relation
to the hematopoietic tissue. This feature is especially important in order to avoid a
false impression of  a reduced fiber content  in fatty and/or edematous bone marrow
samples after treatment. The consensus for measuring myelofibrosis by  clear and
reproducible guidelines achieved by our group should allow for precise grading during
the disease process and after therapy.
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categories (0, 1, 2, 3) according to Georgii12,13 and
Thiele36,15,40 is predominantly based on expert evalua-
tion by pathologists and lacks strict hematologic cri-
teria. Since controversy and discussion continues
about the best practical means to determine cellular-
ity and fiber content routinely and reproducibly in
bone marrow trephine biopsy specimens, a number
of pathologists interested in this issue convened with
the explicit aim of recommending an appropriate
grading system. 
Methods
Following a general as well as critical discussion on
the most widely applied previous scoring systems for
normal values of bone marrow cellularity27-31 and the
grading of myelofibrosis,32,33,17,35,11,15,40 our panel of
hematopathologists reviewed more than 150 trephine
biopsies from various medical institutions. Generally,
specimens included different lesions, but were pre-
dominantly cases of CMPD, in particular CIMF and
essential thrombocythemia, before and after therapy,
derived from adult patients (ranged from 25 to 87
years) and obtained from the posterior iliac crest.
Following fixation in buffered formalin, biopsies were
decalcified in ethylene-diamine tetra-acetate acid and
embedded in paraffin wax. The paraffin sections stud-
ied were usually stained with hematoxylin-eosin and
a silver impregnation method (Gomori; Gordon-
Sweet). Parameters were assessed through a multiple
eye-piece microscope and grading was performed in
an independent fashion by each of the 13 participants.
The hemapathologists were unaware of the clinical
characterization of the patients from whom the sam-
ples had been taken except for age and gender. To
achieve a consensus, the six authors first tried to reach
an agreement by one vote (a consensus requiring
agreement of at least five of the six authors). This was
followed by a subsequent validation of the correspon-
ding results by the rest of the participating investiga-
tors by revoting to test the reproducibility. Overall
consensus was assumed when at least 11 of the 13
pathologists assigned the same score. Particularly fol-
lowing Gomori's silver impregnation technique,
which turned out to be superior to the Gordon-Sweet
reaction, thin (black) reticulin fibers were discriminat-
ed from the thick yellowish appearing collagen fibers
(see also Figure 1D). In case of a focal increase or
regression of fibers, i.e. a patchy distribution of
myelofibrosis, this feature was explicitly recorded in
the final report. Grading of cellularity (amount of
hematopoiesis) was re-assessed in all specimens in
accordance with the age of the patients. 
Results
Unequivocal consensus was reached that a basic
requirement for an assessment of cellularity is a rep-
resentative, i.e. artefact-free, biopsy of a certain
length taken at an orthograde direction (i.e. at right
angles to the cortical bone) and that the sections are
of constant thickness. Consequently, positive charac-
teristics included: a  non-tangential biopsy at least 1.5
cm in length (to enable the evaluation of ten, at least
partially preserved, intertrabecular areas) and an opti-
mal thickness of the paraffin sections ranging
between 3 and 4 mm. Based on the experience gained
from bone marrow specimens without hematologic
disease, cellularity was documented in relation to age
and with respect to normally occurring ranges (Table
2). Quantity and quality (reticulin/collagen) of the
fiber content was determined only in areas of
hematopoiesis by using a scoring system comprising
four grades (Table 3). This semi-quantitative grading
was easily reproducible in samples derived from
patients presenting with different stages of CMPD
(Figures 1 A-D). However, several points must be
considered when applying our scoring system. The
first of these is the quality of the reticulin stain,
which should be assessed by detection of normal
staining in vessel walls as internal controls.
Furthermore, lymphoid nodules and vessels as well
as fibers framing adipocytes must be disregarded.
Finally, areas of prominent scleredema and/or scar-
ring should be included in the overall grading of
myelofibrosis. The 13 pathologists involved in this
study reached a consensus of more than 95%, includ-
ing a similar grade of reproducibility. It was conclud-
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Table 1. Survey of previous semiquantitative scoring systems on
myelofibrosis in normal bone marrow and CMPD.





Lazzarino et al. 16 4
1986
Dekmezian et al. 17 4
1986
Beckman and Brown 35 6
1990
Buhr et al. 11, 14 4
1993, 2003
Georgii et al. 12, 13 4
1996, 1998
Thiele et al. 36, 15, 40 4
1996, 2003
Kvasnicka et al. 37 4
1997
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ed that simplifying former classification systems
(Table 1), in particular regarding myelofibrosis in
relation to bone marrow cellularity, may help to
stage the dynamics of hematologic disorders not only
more accurately, but also in a more easily repro-
ducible way.
Discussion
It has long been recognized that an age-related
quantitative change must be considered when evalu-
ating any given bone marrow biopsy specimen for
hematopoiesis or cellularity.27,3,31 In this context the
question arises whether and to what extent trephine
biopsy material may be compared to aspirates.
Reports in the literature offer rather contradictory
observations30 which are also dependent on the
method of evaluation.29 On the other hand, most
investigators concur that in comparison with smears
and imprints, biopsy examination has proven to be
an important and reliable tool to validate bone mar-
row cellularity.28,3,34,31 Determining alterations in cellu-
larity is not only important in patients following
cytoreductive treatment in order to assess therapeu-
tic efficacy,39,40 but also in CMPD for diagnosis and
staging.13 Moreover, the progression of the disease
process can be documented and consequently differ-
ent risk groups with variable survival patterns may
be defined.
By definition, myelofibrosis is consistent with an
increase in the bone marrow fiber content beyond
the normal range and therefore, this term does not
denote quality (reticulin versus collagen) nor quanti-
ty (borderline to marked). However, in relation to
CMPD, myelofibrosis is frequently used by the clini-
cians to describe a situation characterized by the lab-
oratory findings of anemia, splenomegaly and a
leuko-erythroblastic blood picture with appearance
of tear drop erythrocytes.38,25 It should be emphasized
that these changes indicate an advanced stages of
(collagen) fibrosis associated with myeloid metapla-
sia, but usually these peripheral findings are not
encountered in minimal to mild increase in reticulin
Figure 1. Grading of fiber density and quality, according to the pro-
posed consensus, in bone marrow biopsy specimens of chronic
idiopathic myelofibrosis (CIMF). (A) Grade 0 with single scattered
reticulin fibers consistent with the appearance of the normal bone
marrow. (B) Grade 1 showing a loose meshwork of thin reticulin
fibers with many intersections. (C) Grade 2 with a dense and dif-
fuse increase in reticulin forming extensive intersections and focal
(yellowish) thick collagen fibers. (D) Grade 3 with dense reticulin
fibers intermingled with bundles of (yellowish) collagen and asso-
ciated with endophytic bone formation (osteosclerosis). A-D: silver
impregnation after Gomori, A-D¥180.
Table 2. Normal ranges of bone marrow cellularity for selected
age groups, as adapted from the literature.27-29,3,31




Table 3. Consensus on the grading of myelofibrosis (MF) as adapt-
ed from the literature.32,33,36
Grading Description*
MF - 0 Scattered linear reticulin with no intersections 
(cross-overs) corresponding to normal bone marrow
MF - 1 Loose network of reticulin with many intersections,
especially in perivascular areas
MF - 2 Diffuse and dense increase in reticulin with extensive 
intersections, occasionally with only focal bundles of 
collagen and/or focal osteosclerosis
MF - 3 Diffuse and dense increase in reticulin with extensive 
intersections with coarse bundles of collagen, often 
associated with significant osteosclerosis
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(grades 0 and 1)  in the early stages of CIMF.37,14,15
The present study simplifies all previous descrip-
tions of fiber scorings (Table 1) by reducing them to
four grades, including normal reticulin density, in order
to avoid excessive overlapping and to achieve a higher
degree of reproducibility in routine diagnosis.
Confusion created in former systems,32,33,35 in which
normal reticulin is classified as grade 1, was reduced by
classifying normal as N - normal or grade 0.  
In conclusion, the consensus reached by our group
of experienced hematopathologists,  (including both
European pathologists and a foreign expert) on the
guidelines to be used for measuring cellularity and
bone marrow fiber content may provide a useful tool
for assessing both important  dynamic aspects  of the
disease process, and therapy-related changes.
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